clinical research articles contained 348 clinical trials and 710 observational studies. Of the clinical trials, 297 (85%) were randomized. The observational studies contained 423 longitudinal ones (346 cohort and 77 case-control studies) and the other 287 studies. Figure 1 shows the categories of research articles between 1995 and 2004. The number of observational studies is declining, whereas clinical trials, particularly randomized trials, are increasing. Of the 1118 articles on malignancies, 294 (26%) included hematological malignancies, among which 200 (18%) focused on hematological malignancies. Figure 2 shows the numbers of research articles on hematological malignancies and solid tumors between 1995 and 2004. Basic researches were significantly more common in hematological malignancies than in solid tumors (24/200 (12%) vs 34/824 (4.1%), P ¼ 0.0001; Table 1 ). Non-randomized clinical trials were more frequent in hematological malignancies than in solid tumors (21/200 (11%) vs 28/324 (3.4%), P ¼ 0.0006). Figure 3 shows the number of research articles on solid tumors, hematological malignancies and combined studies per 100 articles published in the four medical journals. The publication frequencies on solid tumors were not different among the four medical journals (7.8-10.9%), whereas those on hematological malignancies were different. Hematological malignancies appeared most frequently in NEJM (4.8%) and least frequently in JAMA (0.4%). NEJM and the Lancet tended to frequently publish clinical trials, particularly randomized trials, both in solid tumors and hematological malignancies. On the contrary, JAMA and Ann Intern Med frequently published observational studies.
Malignancies have been a major topic in medical journals. Approximately 100 research articles are annually published in major clinical journals. In the four medical journals analyzed, 10-15% of the published articles reported on malignancies. This tendency remains relatively stable throughout the study duration, 1995-2004. Aging of the population has recently been accelerated in developed countries and malignancies have surfaced as a social issue. A growing number of pharmaceutical companies have emphasized the development of anticancer agents. 2 Given these backgrounds, the frequency of publications on malignancies is likely to increase in the near future.
These data revealed that the articles on hematological malignancies are frequently published in major medical journals, compared with the low prevalence. Although deaths from hematological malignancies accounts merely for 6.2% of deaths from malignancies in Japan, 1 26% of research articles on malignancies published in major clinical journals reported on hematological malignancies someway. Readers of major clinical journals have more opportunities to be exposed to information on hematological malignancies than that on solid tumors, despite the low prevalence of hematological malignancies. This fact is suggestive. The recent growth of medical specialization has brought about the need of cross-sectional coordination. Many clinicians consider following the major clinical journals such as those presented in this study beneficial to obtain information outside of their own specialties. However, little has reported that there is a certain tendency in topics published in these medical journals. Recognizing the publication tendency of the major clinical journals would be important for clinicians to acquire balanced medical knowledge.
Categories of published studies in hematological malignancies and solid tumors are significantly different (Table 1) . Basic researches were more common in hematological malignancies than in solid tumors (12 vs 4.1%). It is also characteristic of hematological malignancies that non-randomized clinical trials were common. These may be attributable to the nature of the diseases where the pathological mechanisms are frequently elucidated at a molecular level and to the sensitivity to anticancer drugs. Given the sensitivity, hematological malignancies may often be the first candidates in clinical trials on newly developed anticancer drugs and the first results reported in early phases of trials. Such examples are imatinib 3,4 and bortezomib. 5 These four major clinical journals differently present articles on hematological malignancies, in contrast with the similar frequencies in publications on solid tumors. These may reflect the difference in the target readers of each journal. NEJM is considered to be the most prestigious clinical journal and widely read by all medical professionals. JAMA and Ann Intern Med are published by the American Medical Association and the American College of Physicians, respectively, and the target readers of these journals may be different from those of NEJM. The frequent publications of randomized clinical trials which provide the highest evidence level in NEJM and the Lancet may have contributed to the high recognition of these journals.
In conclusion, the publications on hematological malignancies are more frequent than those on solid tumors despite the low prevalence; basic researches and non-randomized clinical trials are more common in hematological malignancies than in solid tumors; and hematological malignancies are presented differently among the major clinical journals. Clinicians would need to be aware of these tendencies of major clinical journals. 
